Xenon Pharmaceuticals (XENE) Competitors

QIAGEN (NYSE:QGEN) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Do institutionals and insiders have more ownership in QGEN or XENE?

70.0% of QIAGEN shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 9.0% of QIAGEN shares are held by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media favor QGEN or XENE?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than QIAGEN. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 10 mentions for QIAGEN. QIAGEN's average media sentiment score of 1.42 beat Xenon Pharmaceuticals' score of 0.44 indicating that QIAGEN is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QIAGEN	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, QGEN or XENE?

QIAGEN has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.

Do analysts prefer QGEN or XENE?

QIAGEN currently has a consensus price target of $49.69, indicating a potential downside of 0.06%. Xenon Pharmaceuticals has a consensus price target of $53.20, indicating a potential upside of 36.97%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than QIAGEN.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QIAGEN	0 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.27
Xenon Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is QGEN or XENE more profitable?

QIAGEN has a net margin of 18.30% compared to Xenon Pharmaceuticals' net margin of 0.00%. QIAGEN's return on equity of 14.77% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QIAGEN	18.30%	14.77%	8.87%
Xenon Pharmaceuticals	N/A	-38.50%	-36.47%

Which has better valuation & earnings, QGEN or XENE?

QIAGEN has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QIAGEN	$1.98B	5.59	$83.59M	$1.69	29.42
Xenon Pharmaceuticals	$9.43M	317.60	-$234.33M	-$3.55	-10.94

Summary

QIAGEN beats Xenon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.